Global Tyrosine Kinase JAK Inhibitors Market Research Report 2021

SKU ID : QYR- 17219839

Publishing Date : 19-Jan-2021

No. of pages : 124

PRICE
2900
5800


  • Janus kinase inhibitors, also known as JAK inhibitors or jakinibs, are a type of medication that functions by inhibiting the activity of one or more of the Janus kinase family of enzymes (JAK1, JAK2, JAK3, TYK2), thereby interfering with the JAK-STAT signaling pathway.

    These inhibitors have therapeutic application in the treatment of cancer and inflammatory diseases such as rheumatoid arthritis. There is interest in their use for various skin conditions. JAK3 inhibitors are attractive as a possible treatment of various autoimmune diseases since its functions is mainly restricted to lymphocytes. Development for a selective JAK3 inhibitors are ongoing.

    In the report, we only count drugs for human beings. And the 1 unit is 1 tablet.
    Tyrosine Kinase JAK Inhibitors is widely used in Rheumatoid Arthritis (RA), Polycythemia Vera (PCV) and Myelofibrosis (MF). The most proportion of Tyrosine Kinase JAK Inhibitors is for Rheumatoid Arthritis (RA), and the proportion in 2017 is about 37%.

    The global Tyrosine Kinase JAK Inhibitors market was valued at US$ 10850 million in 2019 and is expected to reach US$ 320630 million by the end of 2026, growing at a CAGR of 61.5% during 2021-2026.
    This report focuses on Tyrosine Kinase JAK Inhibitors volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Tyrosine Kinase JAK Inhibitors market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.

    Global Tyrosine Kinase JAK Inhibitors Market: Segment Analysis
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

    Segment by Type
    Tofacitinib
    Ruxolitinib
    Baricitinib

    Segment by Application
    Rheumatoid Arthritis (RA)
    Polycythemia Vera (PCV)
    Myelofibrosis (MF)
    Others

    By Region
    North America
    U.S.
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Asia-Pacific
    China
    Japan
    South Korea
    India
    Australia
    Taiwan
    Indonesia
    Thailand
    Malaysia
    Philippines
    Vietnam
    Latin America
    Mexico
    Brazil
    Argentina
    Middle East & Africa
    Turkey
    Saudi Arabia
    U.A.E

    By Company
    Pfizer
    Incyte
    Novartis
    Eli Lilly
    Gilead
    Sanofi
    Galapagos
    AbbVie
    Vertex
    Teva
    Astellas Pharma
    Celgene
    CTI BioPharma

    Frequently Asked Questions



    This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.

    • By product type
    • By End User/Applications
    • By Technology
    • By Region

    The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
    market Reports market Reports